Upgrade Future-Proofs Enterprise Smart Glasses
Vuzix and APX Labs customers can deploy using existing smart glasses and apps and upgrade to the next-generation Vuzix M300 Smart Glasses when they become available.
Vuzix, which supplies video eyewear and smart glasses products, and APX Labs, the developer of the Skylight platform for enterprise wearable technology, announced their Future Proof offer in a Jan. 6, 2016 press release. The program allows customers to begin deployments with Skylight and the Vuzix M100 smart glasses today and upgrade to the next generation Vuzix M300 seamlessly when the M300 begins shipping to customers in summer 2016. The advanced design of the new M300 combined with the latest release of the Skylight software platform will enable large enterprise smart glasses deployments to leverage the latest technology while continuing to use the Vuzix M100 concurrently within the same system.
The Vuzix M300 is the next evolution of Vuzix Smart Glasses designed specifically for industrial use. The M300's design is born from real-world client feedback and industry requirements culminating from over two years of productive use of the Vuzix M100.
Source: Vuzix
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
